GLP-1 Vision Loss (NAION) Lawsuit Update (August 2026)

Ozempic blindness case acquisition has become one of the most actively pursued mass tort intake strategies among plaintiff firms in 2025 and 2026, driven by a consolidating MDL, a scientifically supported causation theory, and a claimant pool that remains largely uncontacted. Advertising costs are still competitive ahead of full market saturation. Firms that establish intake infrastructure now will carry a measurable cost-per-case advantage over later entrants as docket volume and media spend both accelerate.

Why the Ozempic NAION Litigation Is a Firm-Level Business Decision in 2025

NAION stands for non-arteritic anterior ischemic optic neuropathy. It is a sudden, typically permanent loss of vision caused by reduced blood flow to the optic nerve. The link between GLP-1 receptor agonist drugs and NAION gained serious scientific credibility in July 2024 when a study published in JAMA Ophthalmology found that semaglutide users faced a roughly four-times-higher risk of NAION compared to non-users. That study, out of Mass Eye and Ear and Harvard Medical School, changed the trajectory of this litigation overnight.

The core legal theory is failure to warn. Novo Nordisk, the manufacturer of Ozempic and Wegovy, did not include NAION or optic nerve damage in its labeling despite growing evidence of the association. Eli Lilly's tirzepatide products, Mounjaro and Zepbound, are also being pulled into similar claims as the broader GLP-1 lawsuit landscape expands. The same failure-to-warn framework applies to Saxenda and Rybelsus, both semaglutide-class drugs from Novo Nordisk.

For a plaintiff firm, the business question is straightforward: is the case value high enough, is the claimant pool large enough, and is there still room to acquire cases before the economics compress? The honest answer right now is yes on all three counts, but the window is not permanent.

Litigation Landscape: MDL Status, Timing, and What It Means for Case Value

The GLP-1 litigation is consolidating. The primary federal MDL is in the Eastern District of Pennsylvania, where cases involving gastroparesis and other GI injuries have been pending. NAION claims are increasingly being filed as separate actions or added to the existing docket depending on injury type, with some plaintiffs' attorneys filing in New Jersey state court where Novo Nordisk is headquartered, which creates a parallel track that affects strategy.

As of mid-2025, bellwether selection for the vision-loss claims is still in early stages. The GI-related claims are further along procedurally, which is important context for firms doing comparative case triage. Gastroparesis cases have moved faster toward trial-track positioning, but settlement values for NAION claims are expected to be meaningfully higher given the severity and permanence of vision loss. Blindness, even partial, is a catastrophic outcome that juries respond to differently than GI complications. That severity differential is already showing up in how sophisticated firms are pricing their dockets.

Settlement timelines are speculative, but the honest range most plaintiff-side litigators are working with puts global resolution somewhere in the 2026 to 2028 window depending on bellwether outcomes. Firms entering now have time to build a meaningful docket before resolution pressure forces a bad settlement. Firms waiting for a settlement announcement to start advertising will be buying cases at peak CPL with minimal upside.

Morgan and Morgan, who has been aggressive on GLP-1 advertising broadly, has publicized their Ozempic blindness intake. Their case updates signal that larger firms are already competing for this inventory. The fact that Morgan and Morgan is in the market is not a reason to stay out. It is a reason to be disciplined about where and how you advertise.

Ozempic Blindness Case Acquisition: Claimant Pool and Market Demand

Ozempic blindness case acquisition economics start with understanding the addressable pool. Semaglutide prescriptions in the United States have exceeded 10 million active users, with tens of millions more who have used the drug at some point since its 2017 approval. NAION is a relatively rare condition in the general population, affecting roughly 2 to 10 per 100,000 people annually. Even with a four-times elevation in risk among semaglutide users, you are looking at a qualifying population that is meaningful but not infinite.

Current estimates from firms actively running intake suggest somewhere between 50,000 and 150,000 potential NAION claimants in the United States who were on a GLP-1 drug at or near the time of diagnosis. That is a large pool for a pharmaceutical mass tort. The cases filed to date, publicly reported figures suggest somewhere in the low thousands as of early 2025, which means penetration of the addressable pool is still minimal. Geographic concentration is not dramatic. NAION affects users nationwide, and semaglutide prescribing is not regionally skewed the way some environmental torts are. That means national digital advertising works well here.

Saturation in digital channels is building but not yet at the level of, say, Camp Lejeune at its peak or talcum powder during the height of that litigation. Firms that move now will be acquiring cases at a significantly lower cost than firms who enter in 12 to 18 months.

Advertising Economics and Channel Strategy

For firms thinking about channel mix, Facebook and Instagram remain the highest-volume channels for GLP-1 vision-loss leads. The targeting logic is straightforward: Ozempic users skew 40 to 65, they are active on Meta platforms, and the creative connects naturally to the health and medication content they already engage with.

Realistic cost-per-lead on Facebook right now ranges from $80 to $200 for a raw Ozempic blindness lead, depending on targeting precision and creative quality. Cost per signed retainer for a qualified NAION case is running between $1,500 and $4,000 depending on firm intake efficiency and how tightly they screen at the lead level. Those numbers will climb as more advertising dollars enter the market. YouTube pre-roll and programmatic display can supplement volume, but they tend to produce lower-intent leads that require more nurture before signing.

Creative that converts emphasizes the specific injury, sudden or significant vision loss, not GI complications, and references the drug by its brand name. "Ozempic" outperforms "semaglutide" in click-through by a wide margin with consumer audiences. The creative should qualify the lead at the impression level: if someone did not experience meaningful vision loss, they should not click. That pre-qualification in the ad copy directly reduces your cost per qualified lead and improves your conversion rate at intake.

At MTAA, we manage Ozempic blindness campaigns under our transparent cost-plus model, ad spend plus a 15% management fee, no hidden markups on creative or media. We have run more than $250 million in Facebook ad spend for plaintiff firms across 100-plus torts, and the GLP-1 landscape is one we have been in since the early days of the litigation. Firms that want volume without the operational overhead of managing campaigns in-house bring that to us.

Intake and Qualification: What Makes a Signed Case Stick

Intake screening for NAION claims is more specific than most GI-based GLP-1 cases, and getting it right at the front end protects your docket quality. The core qualifying criteria firms are using: confirmed diagnosis of NAION by an ophthalmologist or neuro-ophthalmologist, documented use of semaglutide or another GLP-1 drug within a reasonable period before diagnosis, and medical records that establish the timeline. The ophthalmology records are critical. Cases without a confirmed clinical diagnosis are weak regardless of how compelling the client's story sounds on intake.

Disqualifying factors that experienced plaintiff firms are flagging include prior history of NAION in the same eye, which removes causation, a temporal gap of more than a year between last GLP-1 use and NAION onset, and competing causative conditions like severe hypertension that were poorly controlled and undocumented as secondary to GLP-1 use. Cases where the claimant experienced GI symptoms but no confirmed vision loss are gastroparesis or ileus claims, not NAION claims, and should be triaged accordingly given the different case value and procedural posture.

Retainer flow should be set up to capture signed agreements within 24 to 48 hours of initial contact. The claimants who hesitate and fall out of pipeline are disproportionately the ones you spent the most to acquire. An AI-assisted intake workflow that handles after-hours leads, schedules callbacks, and walks qualified prospects through a digital retainer can materially improve conversion rates. If your firm is not using any AI in intake, even something as simple as an automated SMS follow-up sequence, you are leaving signed cases on the table. For a deeper look at building that infrastructure, the practical frameworks are in my book "A Lawyer's Guide to AI."

How MTAA Runs This Tort

We treat Ozempic blindness case acquisition the same way we approach every pharmaceutical tort we have scaled: with disciplined creative testing, transparent media buying, and intake feedback loops that improve cost per signed case over time. We are not a lead vendor. We build and manage campaigns that are owned by the firm, with full visibility into spend, CPL, and conversion at every stage. Firms working with us on GLP-1 get the benefit of real-time data across a portfolio of campaigns, which means we see what is working faster than any single firm running its own budget in isolation. That cross-campaign intelligence is part of what the 15% fee buys.

We can run national or geo-targeted campaigns, manage creative rotations, and integrate with your intake CRM so the data loop is tight from first click to signed retainer.

The Bottom Line on Ozempic Blindness Case Acquisition in 2025

The NAION branch of the GLP-1 litigation has the three things a firm needs to justify entry: a large and underpenetrated claimant pool, a credible and severe injury supported by peer-reviewed science, and case values that justify current acquisition costs with room to profit at resolution. Ozempic blindness case acquisition is not a speculative bet at this point. The litigation has structure, the science is solid, and the advertising economics are still favorable. The firms that build their dockets in 2025 will be positioned significantly better than firms that wait for the headlines to get louder. If you are ready to evaluate what a campaign would look like for your firm, the math is worth running now.